Skip to main content

Table 2 Details of tumor characteristics, management, and prognosis of 12 patients with pancreatic adenosquamous carcinoma.

From: Clinicopathologic features and outcomes following surgery for pancreatic adenosquamous carcinoma

Case Tumor location Size (cm) Operative method Intraoperative irradiation Postoperative chemotherapy Stage* (TNM) Survival (months)
1 Head 6 Biopsy, bypass ND ND III (T4N1M0) 4.04
2 Head 3.5 PD ND ND IIB (T2N1M0) 2.50
3 Body and tail 8 Biopsy, bypass ND ND IV (T4N1M1) 1.12
4 Head 6 Biospy 1,800 cGy ND III (T4N0M0) 22.42
5 Tail 8 Biopsy 2,000 cGy Gemcitabine III (T4N1M0) 5.42
6 Body 8 Biopsy, bypass ND Tegafur III (T4N1M0) 4.41
7 Head 3.8 PD ND Gemcitabine, Fluorouracil IIB (T2N1M0) 6.84
8 Head 5.5 PD ND Gemcitabine IIB (T3N1M0) 6.51
9 Body 7 subtotal P, total G, S ND Tegafur, Uracil IIB (T3N1M0) 11.84
10 Tail 5 distal P, S ND ND IIB (T2N1M0) 10.82
11 Tail 8 distal P, total G, S ND Gemcitabine, Cisplatin IIB (T3N1M0) 3.68
12 Body and Tail 6.5 subtotal P, S ND Gemcitabine IIB (T3N1M0) 4.08
  1. G, gastrectomy; ND, not done; P, pancreatectomy; PD, pancreaticoduodenectomy; S, splenectomy; *, clinical and pathological.